The effect of acute magnesium loading on the maximal exercise performance of stable chronic obstructive pulmonary disease patients

Angélica Florípedes do Amaral, Lourenco Gallo Jr, Hélio Vannucchi, Júlio César Crescêncio, Elcio Oliveira Vianna, José Antônio Baddini Martinez, Angélica Florípedes do Amaral, Lourenco Gallo Jr, Hélio Vannucchi, Júlio César Crescêncio, Elcio Oliveira Vianna, José Antônio Baddini Martinez

Abstract

Objective: The potential influence of magnesium on exercise performance is a subject of increasing interest. Magnesium has been shown to have bronchodilatatory properties in asthma and chronic obstructive pulmonary disease patients. The aim of this study was to investigate the effects of acute magnesium IV loading on the aerobic exercise performance of stable chronic obstructive pulmonary disease patients.

Methods: Twenty male chronic obstructive pulmonary disease patients (66.2 + 8.3 years old, FEV1: 49.3+19.8%) received an IV infusion of 2 g of either magnesium sulfate or saline on two randomly assigned occasions approximately two days apart. Spirometry was performed both before and 45 minutes after the infusions. A symptom-limited incremental maximal cardiopulmonary test was performed on a cycle ergometer at approximately 100 minutes after the end of the infusion.

Results: Magnesium infusion was associated with significant reductions in the functional residual capacity (-0.41 l) and residual volume (-0.47 l), the mean arterial blood pressure (-5.6 mmHg) and the cardiac double product (734.8 mmHg.bpm) at rest. Magnesium treatment led to significant increases in the maximal load reached (+8 w) and the respiratory exchange ratio (0.06) at peak exercise. The subgroup of patients who showed increases in the work load equal to or greater than 5 w also exhibited significantly greater improvements in inspiratory capacity (0.29 l).

Conclusions: The acute IV loading of magnesium promotes a reduction in static lung hyperinflation and improves the exercise performance in stable chronic obstructive pulmonary disease patients. Improvements in respiratory mechanics appear to be responsible for the latter finding.

Trial registration: ClinicalTrials.gov NCT00500864.

Conflict of interest statement

No potential conflict of interest was reported.

Figures

Figure 1
Figure 1
Mg plasma levels after infusion of 2 g of magnesium sulfate or saline in 20 male COPD patients.

References

    1. Saris NE, Mervaala E, Karppanen H, Khawaja JA, Lewestam A. Magnesium. An update on physiological, clinical and analytical aspects. Clin Chim Acta. 2000;294(1-2):1–26.
    1. Finstad EW, Newhouse IJ, Lukaski HC, Mcaulifffe JE, Stewart CR. The effects of magnesium supplementation on exercise performance. Med Sci Sports Exerc. 2001;33(3):493–8.
    1. Newhouse IJ, Finstad EW. The effects of magnesium supplementation on exercise performance. Clin J Sport Med. 2000;10:195–200.
    1. Lukaski HC, Nielsen FH. Dietary magnesium depletion affects metabolic responses during submaximal exercise in postmenopausal women. J Nutr. 2002;132(5):930–5.
    1. Cinar V, Nizamlioğlu M, Moğulkoc R. The effect of magnesium supplementation on lactate levels of sportsmen and sedanter. Acta Physiol Hung. 2006;93(2-3):137–44.
    1. Shechter M, Bairey Merz CN, Stuehlinger HG, Slany J, Pochinger O, Rabinowitz B. Effects of oral magnesium therapy on exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease. Am J Cardiol. 2003;91(5):517–21.
    1. Sabino PG, Silva BM, Brunetto AF. Nutritional status is related to fat-free mass, exercise capacity and inspiratory strength in severe chronic obstructive pulmonary disease patients. Clinics. 2010;65(6):599–605.
    1. Britton J, Pavord I, Richards K, Wisniewski A, Knox A, Lewis S, et al. Dietary magnesium, lung function, wheezing, and airway hyperreactivity in a random adult population sample. Lancet. 1994;344(8919):357–62.
    1. Gilliland FD, Berhane KT, Li YF, Kim DH, Margolis HG. Dietary magnesium, potassium, sodium, and children's lung function. Am J Epidemiol. 2002;155(2):125–31.
    1. Cerci-Neto A, Ferreira Filho F, Parreira JS. The relative frequency of hypomagnesemia in outpatients with chronic airfl ow limitation treated at a referral center in the north of the state of Paraná, Brazil. J Bras Pneumol. 2006;32(4):294–300.
    1. Ruljancic N, Popovic-Grle S, Rumenjak V, Sokolic B, Malic A, Mihanovic M, et al. COPD: magnesium in the plasma and polymorphonuclear cells of patients during a stable phase. COPD. 2007;4(1):41–7.
    1. Skorodin MS, Tenholder MF, Yetter B, Owen KA, Waller RF, Kahndelwahl S, et al. Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Arch Intern Med. 1995;155(5):496–500.
    1. Cheuk DK, Chau TC, Lee SL. A meta-analysis on intravenous magnesium sulfate for treating acute asthma. 2005;90(1):74–7. Arch Dis Child.
    1. Blitz M, Blitz S, Hughes R, Diner B, Beasley R, Knopp J, et al. Aerosolized magnesium sulfate for acute asthma: a systematic review. Chest. 2005;128(1):337–44.
    1. Bichara MD, Goldman RD. Magnesium for treatment of asthma in children. Can Fam Physician. 2009;55(9):887–9.
    1. Abreu González J, Hernández Garcia C, Abreu González P, et al. [Effect of intravenous magnesium sulfate on chronic obstructive pulmonary disease exacerbations requiring hospitalization: a randomized placebo controlled trial] Arch Bronchoneumol. 2006;42(5):384–7.
    1. Amaral AF, Rodrigues-Júnior AL, Terra Filho J, Vannucchi H, Martinez JAB. Effects of acute magnesium loading on pulmonary function of stable COPD patients. Med Sci Monit. 2008;14(10):LE15–6; author reply E16-7.
    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Available at: . Accessed March 9, 2011.
    1. Bloch H, Silverman R, Mancherje N, Grant S, Jaqminas L, Scharf SM. Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest. 1995;107(6):1576–81.
    1. Standardization of spirometry-1987 update. Statement of the American Thoracic Society. Am Rev Respir Dis. 1987;136:1285–98.
    1. Crapo RA, Morris AH, Gardner RM. References spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis. 1981;123(6):659–64.
    1. Crapo RO, Morris AH, Clayton PD, Nixon CR. Lung volumes in healthy nonsmoking adults. Bull Eur Physiopathol Respir. 1982;18(3):419–25.
    1. Sociedade Brasileira de Cardiologia. III Guidelines of Sociedade Brasileira de Cardiologia on the exercise test. Arq Bras Cardiol. 2010;95(5 Suppl 1):1–26.
    1. Grizzle JE. The two-period cross-over design and its use in clinical trials. Biometrics. 1965;21:467–80.
    1. Hills M, Armitage P. The two period cross-over clinical trial. Br J Clin Pharmacol. 1979;8(1):7–20.
    1. Fergunson G. Why does the lung hyperinflate. Proc Am Thorac Soc. 2006;3(2):176–9.
    1. Spivey MH, Skobeloff EM, Levin RM. Effect of magnesium chloride on rabbit bronchial smooth muscle. Ann Emerg Med. 1990;19(1):1107–12.
    1. Del Castillo J, Engbauk L. The nature of the neuromuscular block produced by magnesium. 1954;124(2):370–84. J Physiol.
    1. Nadler JL, Goodson S, Rude RK. Evidence that prostacyclin mediates the vascular action of magnesium in humans. Hypertension. 1987;9(4):379–83.
    1. Kemp PA, Gardiner SM, March JE, Bennett T, Rubin PC. Effects of NG-nitro-L-arginine methyl ester on regional haemodynamic responses to MgSO4 in conscious rats. Br J Pharmacol. 1994;111(1):325–31.
    1. Yogi A, Callera GE, Antunes TT, Tostes RC, Touyz RM. Vascular biology of magnesium and its transporters in hypertension. Circ J. 2011;75(2):237–45.
    1. Wukitsch MW, Petterson MT, Tobler DR, Pologe JA. Pulse oximetry: analysis of theory, technology, and practice. J Clin Monit. 1988;4(4):290–301.
    1. O'Donnell DE, Webb KA. The major limitation to exercise performance in COPD is dynamic hyperinflation. J Appl Physiol. 2008;105(2):753–5; discussion 755-7.
    1. Laveneziana P, Parker CM, O'Donnell DE. Ventilatory constraints and dyspnea during exercise in chronic obstructive pulmonary disease. Appl Physiol Nutr Metab. 2007;32(6):1225–38.
    1. Ofir D, Laveneziana P, Webb KA, Lam YM, O'Donnell DE. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(6):622–9.
    1. Chen YJ, Chen HY, Wang MF, Hsu MH, Liang WM, Cheng FC. Effects of magnesium on exercise performance and plasma glucose and lactate concentrations in rats using a novel blood-sampling technique. Appl Physiol Nutr Metab. 2009;34(6):1040–7.
    1. Cheng SM, Yang DY, Lee CP, Pan HC, Lin MT, Chen SH, et al. Effects of magnesium sulfate on dynamic changes of brain glucose and its metabolites during a short-term forced swimming in gerbils. Eur J Appl Physiol. 2007;99(6):695–9.
    1. Cheng SM, Yang LL, Chen SH, Hsu MH, Chen IJ, Cheng FC. Magnesium sulfate enhances exercise performance and manipulates dynamic changes in peripheral glucose utilization. Eur J Appl Physiol. 2010;108(2):363–9.
    1. Cinar V, Mogulkoc R, Baltaci AK, Polat Y. Adrenocorticotropic hormone and cortisol levels in athletes and sedentary subjects at rest and exhaustion:effects of magnesium supplementation. Biol Trace Elem Res. 2008;121(3):215–20.
    1. Mooren FC, Golf SW, Lechtermann A, Völer K. Alterations of ionized Mg2+ in human blood after exercise. Life Sci. 2005;77(11):1211–25.
    1. Fuentes JC, Salmon AA, Silver MA. Acute and chronic oral magnesium supplementation: effects on endothelial function, exercise capacity, and quality of life in patients with symptomatic heart failure. Congest Heart Fail. 2006;12(1):9–13.
    1. Shechter M, Sharir M, Labrador MJ, Forrester M, Silver B, Bairey Merz CN. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation. 2000;102(19):2353–8.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir